MADRIGAL PHARMACEUTICALS INC (MDGL) Forecast, Price Target & Analyst Ratings

Q: What is the average price target for MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

23 analysts have analysed MDGL and the average price target is 672.72 USD. This implies a price increase of 28.11% is expected in the next year compared to the current price of 525.13.

NASDAQ:MDGL • US5588681057

525.13 USD

-4.01 (-0.76%)

Last: Apr 23, 2026, 10:59 AM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MADRIGAL PHARMACEUTICALS INC (MDGL).

Consensus Price Target

Price Target

$672.72

+ 28.11% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 12, 2026
Period: Q1 / 2026
EPS Estimate: -$4.31
Revenue Estimate: 307.31M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

81.74%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$672.72

Upside

+ 28.11%

From current price of $525.13 to mean target of $672.72, Based on 23 analyst forecasts

Low

$534.29

Median

$652.80

High

$1,012.20

Price Target Revisions

1 Month

0.14%

3 Months

8.59%

Price Target Summary

23 Wall Street analysts provided a forecast for the next 12 months for MDGL. The average price target is 672.72 USD. This implies a price increase of 28.11% is expected in the next year compared to the current price of 525.13.

The average price target has been revised upward by 8.59% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

81.74%

MDGL was analyzed by 23 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about MDGL.

In the previous month the buy percentage consensus was at a similar level.

MDGL was analyzed by 23 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-02-20	B of A Securities	Maintains	Neutral -> Neutral
2026-01-28	Barclays	Initiate	Overweight
2026-01-20	Citizens	Maintains	Market Outperform -> Market Outperform
2025-12-19	Piper Sandler	Maintains	Overweight -> Overweight
2025-12-11	B. Riley Securities	Maintains	Buy -> Buy
2025-11-21	HC Wainwright & Co.	Maintains	Buy -> Buy
2025-11-20	Oppenheimer	Maintains	Outperform -> Outperform
2025-11-19	Truist Securities	Maintains	Buy -> Buy
2025-11-13	Canaccord Genuity	Maintains	Buy -> Buy
2025-11-11	HC Wainwright & Co.	Maintains	Buy -> Buy
2025-11-05	Citizens	Maintains	Market Outperform -> Market Outperform
2025-11-05	Cantor Fitzgerald	Upgrade	Neutral -> Overweight
2025-11-03	B of A Securities	Upgrade	Underperform -> Neutral
2025-10-15	Truist Securities	Initiate	Buy
2025-10-15	Piper Sandler	Maintains	Overweight -> Overweight
2025-10-10	Oppenheimer	Maintains	Outperform -> Outperform
2025-09-29	B. Riley Securities	Maintains	Buy -> Buy
2025-09-12	Canaccord Genuity	Maintains	Buy -> Buy
2025-08-26	TD Cowen	Maintains	Buy -> Buy
2025-08-20	JMP Securities	Maintains	Market Outperform -> Market Outperform
2025-08-12	UBS	Maintains	Buy -> Buy
2025-08-06	Canaccord Genuity	Maintains	Buy -> Buy
2025-05-02	UBS	Maintains	Buy -> Buy
2025-05-02	B. Riley Securities	Reiterate	Buy -> Buy
2025-05-02	Canaccord Genuity	Maintains	Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 12, 2026
Period: Q1 / 2026
EPS Estimate: -$4.31
Revenue Estimate: 307.31M
Revenue Q2Q: 123.91%
EPS Q2Q: -29.82%
Number of Analysts: 16

Next Earnings Revisions

Revenue (1 Month)

0.10%

Revenue (3 Months)

-1.53%

EPS (1 Month)

-3.52%

EPS (3 Months)

-406.86%

Next Earnings Summary

MDGL is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -4.31 USD and the consensus revenue estimate is 307.31M USD.

The next earnings revenue estimate has been revised downward by 1.53% in the past 3 months.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth		180.133M	958.403M 432.05%	1.518B 58.39%	2.255B 48.55%	3.114B 38.09%	3.984B 27.94%	4.88B 22.49%	5.334B 9.30%	5.976B 12.04%	6.027B 0.85%
EBITDA YoY % growth	-379.969M -29.62%	-496.779M -30.74%	-298.591M 39.89%	-170.473M 42.91%	377.35M 321.36%	918.14M 143.31%	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-380.496M -29.60%	-497.875M -30.85%	-300.097M 39.72%	-118.982M 60.35%	354.48M 397.93%	944.21M 166.36%	1.752B 85.55%	2.551B 45.61%	3.02B 18.38%	3.564B 18.01%	3.534B -0.84%
Operating Margin	N/A	-276.39%	-31.31%	-7.84%	15.72%	30.32%	43.98%	52.27%	56.62%	59.64%	58.64%
EPS YoY % growth	-19.94 -15.73%	-22.11 -10.88%	-12.75 42.33%	-5.29 58.53%	12.03 327.57%	32.44 169.59%	59.15 82.37%	83.94 41.91%	108.70 29.49%	136.13 25.23%	152.87 12.30%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26	Q1 / 27	Q2 / 27	Q3 / 27	Q4 / 27	Q1 / 28	Q2 / 28	Q3 / 28	Q4 / 28
EPS Q2Q % growth	-4.31 -29.82%	-1.02 46.21%	-0.32 93.62%	0.64 124.84%	-0.93 78.45%	1.17 214.22%	2.38 850.02%	5.39 743.88%	1.74 287.15%	5.24 348.49%	5.06 113.01%	8.06 49.58%
Revenue Q2Q % growth	307.31M 123.91%	354.67M 66.67%	395.24M 37.59%	445.56M 38.77%	412.85M 34.34%	472.68M 33.27%	549.11M 38.93%	657.23M 47.51%	N/A	N/A	N/A	N/A
EBITDA Q2Q % growth	-79.392M -0.58%	-55.274M -19.01%	14.826M 113.14%	71.079M 222.33%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-101.075M -27.44%	-26.339M 44.20%	-9.917M 91.30%	14.584M 124.47%	-69.519M 31.22%	-11.227M 57.37%	71.605M 822.02%	206.75M 1,317.65%	N/A	N/A	N/A	N/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

65.63%

EPS Next 5 Year

53.72%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

47.59%

Revenue Next 5 Year

38.18%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

77.55%

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MADRIGAL PHARMACEUTICALS INC / MDGL Forecast FAQ

What is the average price target for MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

23 analysts have analysed MDGL and the average price target is 672.72 USD. This implies a price increase of 28.11% is expected in the next year compared to the current price of 525.13.

Can you provide the upcoming earnings date for MADRIGAL PHARMACEUTICALS INC?

MADRIGAL PHARMACEUTICALS INC (MDGL) will report earnings on 2026-05-12, before the market open.

What are the consensus estimates for MDGL stock next earnings?

The consensus EPS estimate for the next earnings of MADRIGAL PHARMACEUTICALS INC (MDGL) is -4.31 USD and the consensus revenue estimate is 307.31M USD.

How many analysts cover MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

The number of analysts covering MADRIGAL PHARMACEUTICALS INC (MDGL) is 23.

Analyst forecast overview

Forecast Snapshot